For anyone interested Rxi pharmaceuticals (RXII) trades on Nasdaq Capital Market at $3 per share , and is approaching the moment where it will reveal phase 2 results. Risky of course but if successful it could gap up big with a small float of only 16 million shares. here is some Due diligence info for anyone that wants to check it out http://www.biotechpicklist.com/biotechpicklist/rxii-rxi-pharmaceuticals/ Also the official company website for the company can be seen here http://www.rxipharma.com/ Basically in essence this company uses RNAi which is RNAi interference that means the ability to down regulate the genes of diseases so they are no longer expressed in the body. But unlike other RNAi biotechnology companies like ARWR, TKMR, DRNA etc. , RXII has chosen to do something different instead of a delivery vehicle (basically a shield around the RNAi strand) and has turned its RNAi drug compound into a drug compound that can be delivered through the body without degrading and without toxicity. Its sd-rxRNA platform is known as a self delivering oligonucleotide. For anyone interested before this major catalyst i recommend checking it out.